Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hellmann

Showing results (81-90 of 235) with videos related to

Pageof 24
Sort By:
Cancer Cell|June 21, 2024
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsGabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, et al.
Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2020
Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitorsN Shaverdian, J Beattie, M Thor, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
Nature|November 14, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyMarta Łuksza, Nadeem Riaz, Vladimir Makarov, et al.
Advances in Radiation Oncology|September 12, 2018
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionDonata von Reibnitz, Jamie E Chaft, Abraham J Wu, et al.
Nature|May 18, 2017
Chromatin states define tumour-specific T cell dysfunction and reprogrammingMary Philip, Lauren Fairchild, Liping Sun, et al.
ESMO Open|June 27, 2018
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)Filippo de Marinis, Fortunato Ciardiello, Paul Baas, et al.
Pageof 24

Showing results (81-90 of 235) with videos related to

Sort By:
Pageof 24
Cancer Cell|June 21, 2024
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsGabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, et al.
Plos One|August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumorsKathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2020
Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitorsN Shaverdian, J Beattie, M Thor, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorV R Belum, B Benhuri, M A Postow, et al.
Nature|November 14, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapyMarta Łuksza, Nadeem Riaz, Vladimir Makarov, et al.
Advances in Radiation Oncology|September 12, 2018
Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionDonata von Reibnitz, Jamie E Chaft, Abraham J Wu, et al.
Nature|May 18, 2017
Chromatin states define tumour-specific T cell dysfunction and reprogrammingMary Philip, Lauren Fairchild, Liping Sun, et al.
ESMO Open|June 27, 2018
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)Filippo de Marinis, Fortunato Ciardiello, Paul Baas, et al.
Pageof 24